Lilly’s Zepbound Beats Wegovy in Weight Loss Trial Results

The trial also showed that treatment with Zepbound achieved a superior average waist circumference reduction of 18.4 centimeters (cm), while those treated with Wegovy saw an average reduction of 13 cm. Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. Lilly reported in December that its obesity drug had already met the main goal, leading to 47 per cent more weight loss than those who received Wegovy. Full data from the study was reported by the company in a press release and presented at the European Congress on Obesity. The data is the first head-to-head trial comparing the wildly popular medicines, and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market estimated to reach more than $150 billion annually by the next decade.It comes days after CVS Health's decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favoring Wegovy. Zepbound helped nearly 25 per cent more participants lose more than 15 per cent of their weight compared to Wegovy, Lilly said on Sunday.The trial also showed that treatment with Zepbound achieved a superior average waist circumference reduction of 18.4 centimeters (cm), while those treated with Wegovy saw an average reduction of 13 cm. While Lilly's drug mimics two gut hormones to help reduce weight, Wegovy has a single mode of action. U.S. approvals for Zepbound and Wegovy were based on separate trials in which Lilly's drug helped patients lose more than 22 per cent of their weight after 72 weeks, while Wegovy led to 15 per cent weight loss after 68 weeks.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!